US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

 
• By Derrick Gingery
  
increasing costs
The FDA's cost to review NME NDAs and BLAs in FY 2023 was the second-highest total since FY 2009. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from User Fees

More from Pathways & Standards